IS2759B - CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi - Google Patents

CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi

Info

Publication number: IS2759B
Authority: IS; Iceland
Prior art keywords: preparations; drug; manufacture; receptor antagonists; cgrp receptor
Prior art date: 2003-04-15

Application number

IS8055A

Other languages

English (en)

Other versions

IS8055A (is

Inventor

Christopher S Burgey

Theresa M Williams

Zhengwu J Deng

Diem N Nguyen

Daniel V Paone

Anthony W Shaw

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-15

Filing date

2005-09-29

Publication date

2011-10-15

2005-09-29 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2005-09-29 Publication of IS8055A publication Critical patent/IS8055A/is

2011-10-15 Publication of IS2759B publication Critical patent/IS2759B/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Hematology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Addiction (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IS8055A 2003-04-15 2005-09-29 CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi IS2759B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46308903P	2003-04-15	2003-04-15
US51035203P	2003-10-10	2003-10-10
PCT/US2004/011280 WO2004092168A1 (en)	2003-04-15	2004-04-09	Cgrp receptor antagonists

Publications (2)

Publication Number	Publication Date
IS8055A IS8055A (is)	2005-09-29
IS2759B true IS2759B (is)	2011-10-15

Family

ID=33303112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8055A IS2759B (is)	2003-04-15	2005-09-29	CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi

Country Status (32)

Country	Link
US (6)	US6953790B2 (is)
EP (2)	EP1638969B1 (is)
JP (1)	JP3967766B2 (is)
KR (1)	KR100769030B1 (is)
CN (1)	CN100384843C (is)
AR (1)	AR045887A1 (is)
AT (1)	ATE413400T1 (is)
AU (1)	AU2004230926B2 (is)
BR (1)	BRPI0409601A (is)
CA (1)	CA2522220C (is)
CL (1)	CL2004000788A1 (is)
CO (1)	CO5640130A2 (is)
CY (1)	CY1108714T1 (is)
DE (1)	DE602004017608D1 (is)
DK (1)	DK1638969T3 (is)
EC (1)	ECSP056097A (is)
ES (1)	ES2314417T3 (is)
HR (1)	HRP20080666T3 (is)
IS (1)	IS2759B (is)
JO (1)	JO2355B1 (is)
MA (1)	MA27728A1 (is)
MX (1)	MXPA05011166A (is)
NO (1)	NO327655B1 (is)
NZ (1)	NZ543357A (is)
PE (1)	PE20050020A1 (is)
PL (1)	PL1638969T3 (is)
PT (1)	PT1638969E (is)
RU (1)	RU2308458C2 (is)
SI (1)	SI1638969T1 (is)
TW (1)	TWI314931B (is)
UA (1)	UA82877C2 (is)
WO (2)	WO2004092168A1 (is)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2616539T3 (es) *	2002-06-05	2017-06-13	Bristol-Myers Squibb Company	Antagonistas de receptores de péptidos relacionados con el gen de calcitonina
US7842808B2 (en)	2002-06-05	2010-11-30	Bristol-Myers Squibb Company	Anti-migraine spirocycles
US7220862B2 (en)	2002-06-05	2007-05-22	Bristol-Myers Squibb Company	Calcitonin gene related peptide receptor antagonists
ATE466860T1 (de) *	2003-04-15	2010-05-15	Merck Sharp & Dohme	Cgrp-rezeptorantagonisten
GB0310881D0 (en) *	2003-05-12	2003-06-18	Merck Sharp & Dohme	Pharmaceutical formulation
JP4705911B2 (ja) *	2003-06-26	2011-06-22	メルク・シャープ・エンド・ドーム・コーポレイション	ベンゾジアゼピンｃｇｒｐ受容体拮抗物質
WO2005013894A2 (en) *	2003-06-26	2005-02-17	Merck & Co., Inc.	Benzodiazepine cgrp receptor antagonists
US7569578B2 (en)	2003-12-05	2009-08-04	Bristol-Meyers Squibb Company	Heterocyclic anti-migraine agents
EP1765805B1 (en) *	2004-01-29	2013-11-20	Merck Sharp & Dohme Corp.	Cgrp receptor antagonists
US20090209491A1 (en) *	2004-02-23	2009-08-20	Trustees Of Tufts College	Lactams as conformationally constrained peptidomimetic inhibitors
TW200533398A (en)	2004-03-29	2005-10-16	Bristol Myers Squibb Co	Novel therapeutic agents for the treatment of migraine
JP2008515895A (ja) *	2004-10-07	2008-05-15	メルクエンドカムパニーインコーポレーテッド	Ｃｇｒｐ受容体拮抗薬
JP2008516957A (ja) *	2004-10-14	2008-05-22	メルクエンドカムパニーインコーポレーテッド	Ｃｇｒｐ受容体拮抗薬
DE602005027230D1 (de)	2004-10-22	2011-05-12	Merck Sharp & Dohme	Cgrp-rezeptorantagonisten
US7384931B2 (en)	2004-11-03	2008-06-10	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) *	2004-11-03	2008-06-10	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en)	2004-12-03	2008-11-11	Bristol-Myers Squibb Company	Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
GB2423085C (en) *	2005-02-11	2011-11-09	Cambridge Entpr Ltd	Ligands for G-protein coupled receptors
GB2467060B (en) *	2005-02-11	2010-09-01	Cambridge Entpr Ltd	Ligands for G-protein coupled receptors
US7994325B2 (en)	2005-03-14	2011-08-09	Merck Sharp & Dohme Corp.	CGRP receptor antagonists
US7834007B2 (en)	2005-08-25	2010-11-16	Bristol-Myers Squibb Company	CGRP antagonists
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
DK3045182T3 (en)	2005-11-14	2018-03-19	Teva Pharmaceuticals Int Gmbh	ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
CN100371327C (zh) *	2005-11-17	2008-02-27	江苏工业学院	2-氨基-6-烷氧基-3-硝基吡啶的一步合成法
EP1954135B1 (en) *	2005-11-18	2012-10-10	Merck Sharp & Dohme Corp.	Spirolactam aryl cgrp receptor antagonists
AU2007238895A1 (en) *	2006-04-10	2007-10-25	Merck Sharp & Dohme Corp.	Process for the preparation of CGRP antagonist
EP2007763A2 (en) *	2006-04-10	2008-12-31	Merck & Co., Inc.	Process for the preparation of pyridine heterocycle cgrp antagonist intermediate
CA2647683A1 (en)	2006-04-10	2007-10-25	Merck & Co., Inc.	Process for the preparation of caprolactam cgrp antagonist intermediate
WO2007120592A1 (en) *	2006-04-10	2007-10-25	Merck & Co., Inc.	Cgrp antagonist salt
ES2368456T3 (es)	2006-05-02	2011-11-17	Bristol-Myers Squibb Company	Compuestos restringidos como antagonistas del receptor de cgrp.
US7470680B2 (en) *	2006-05-03	2008-12-30	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
CN101443323A (zh) *	2006-05-09	2009-05-27	默克公司	取代的螺环cgrp受体拮抗剂
US8163737B2 (en)	2006-06-13	2012-04-24	Vertex Pharmaceuticals Incorporated	CGRP receptor antagonists
TW200813019A (en) *	2006-06-13	2008-03-16	Vertex Pharma	CGRP receptor antagonists
US7834000B2 (en) *	2006-06-13	2010-11-16	Vertex Pharmaceuticals Incorporated	CGRP receptor antagonists
US8227603B2 (en)	2006-08-01	2012-07-24	Cytokinetics, Inc.	Modulating skeletal muscle
US8299248B2 (en)	2006-08-02	2012-10-30	Cytokinetics, Incorporated	Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
DK2583970T3 (en)	2006-08-02	2015-11-16	Cytokinetics Inc	Certain chemical entities, compositions, and methods comprising imidazopyrimidines
CN101511184A (zh) *	2006-09-08	2009-08-19	默克公司	用于口服给药cgrp拮抗剂的液体药物制剂
ES2379744T3 (es)	2007-05-23	2012-05-03	Merck Sharp & Dohme Corp.	Antagonistas de piridil-piperidina de los receptores de orexinas
GB0712392D0 (en) *	2007-06-26	2007-08-01	Glaxo Group Ltd	Novel compounds
US20090075977A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched mk0974
CA2722536A1 (en)	2008-02-05	2009-08-13	Merck & Co., Inc.	Prodrugs of cgrp receptor antagonist
CA2711367A1 (en) *	2008-02-19	2009-08-27	Merck Sharp & Dohme Corp.	Imidazobenzazepine cgrp receptor antagonists
WO2009109911A1 (en)	2008-03-04	2009-09-11	Pfizer Limited	Methods of treating chronic pain
US8143403B2 (en)	2008-04-11	2012-03-27	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8044043B2 (en)	2008-04-11	2011-10-25	Bristol-Myers Squibb Company	CGRP receptor antagonists
EP2303238A1 (en) *	2008-06-30	2011-04-06	Merck Sharp & Dohme Corp.	Solid dosage formulations of telcagepant potassium
JP2012506379A (ja)	2008-10-21	2012-03-15	メルク・シャープ・エンド・ドーム・コーポレイション	二置換アゼパンオレキシン受容体アンタゴニスト
US8715715B2 (en) *	2008-11-03	2014-05-06	Nal Pharmaceuticals Ltd.	Dosage form for insertion into the mouth
IN2012DN02521A (is)	2009-08-28	2015-08-28	Rinat Neuroscience Corp
US8314117B2 (en) *	2009-10-14	2012-11-20	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8669368B2 (en)	2010-10-12	2014-03-11	Bristol-Myers Squibb Company	Process for the preparation of cycloheptapyridine CGRP receptor antagonists
TWI501968B (zh)	2010-11-12	2015-10-01	Merck Sharp & Dohme	六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
CA2830348A1 (en) *	2011-03-18	2012-09-27	Merck Sharp & Dohme Corp.	Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US8748429B2 (en)	2011-04-12	2014-06-10	Bristol-Myers Squibb Company	CGRP receptor antagonists
BR112013029951B1 (pt)	2011-05-20	2020-10-20	Alderbio Holdings Llc	composição farmacêutica e uso de anticorpos ou fragmentos de anticorpos anti-cgrp para tratar ou prevenir formas de diarreia crônicas e agudas
AU2012258980B8 (en)	2011-05-20	2017-06-15	H. Lundbeck A/S	Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
TR201904088T4 (tr)	2011-05-20	2019-05-21	Alderbio Holdings Llc	Anti-CGRP bileşimleri ve bunların kullanımları.
WO2013010015A2 (en)	2011-07-13	2013-01-17	Cytokinetics, Inc.	Combination als therapy
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
ES2746031T3 (es)	2012-02-27	2020-03-04	Bristol Myers Squibb Co	Sal de N-(5S,6S,9R)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5H-ciclohepta[B]piridin-9-IL-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidina-1-carboxilato
BR112014024203B1 (pt)	2012-03-29	2019-09-03	Bayer Ip Gmbh	derivados de 5-aminopirimidina e sua utilização para o controle do crescimento de plantas indesejadas
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
US12168004B2 (en)	2014-02-05	2024-12-17	Merck Sharp & Dohme Llc	Treatment of migraine
RU2019123406A (ru)	2014-02-05	2019-10-03	Мерк Шарп И Доум Корп.	Технология приготовления таблеток для cgrp-активных соединений
US9896502B2 (en)	2014-03-21	2018-02-20	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
GB201417707D0 (en)	2014-10-07	2014-11-19	Viral Ltd	Pharmaceutical compounds
WO2017001434A1 (en) *	2015-06-29	2017-01-05	Galderma Research & Development	Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519195D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
GB201519194D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP receptor antagonists
GB201519196D0 (en)	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
WO2018055574A1 (en)	2016-09-23	2018-03-29	Teva Pharmaceuticals International Gmbh	Treating refractory migraine
EP3366286A1 (en)	2017-02-22	2018-08-29	Johannes Keller	Compounds for treating sepsis
GB201707938D0 (en)	2017-05-17	2017-06-28	Univ Sheffield	Compounds
US11685729B2 (en)	2018-01-19	2023-06-27	Idorsia Pharmaceuticals Ltd.	C5a receptor modulators
US12383545B1 (en)	2018-06-08	2025-08-12	Allergan Pharmaceuticals International Limited	Treatment of migraine
CN108892635A (zh) *	2018-09-07	2018-11-27	江苏工程职业技术学院	一种西沙必利关键中间体的制备方法
MA54704A (fr)	2019-01-08	2022-04-13	H Lundbeck As	Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
GB201908430D0 (en) *	2019-06-12	2019-07-24	Heptares Therapeutics Ltd	Cgrp antagonist compounds
GB201908420D0 (en)	2019-06-12	2019-07-24	Heptares Therapeutics Ltd	Cgrp antagonist compounds
SG10202003296VA (en)	2020-04-06	2021-11-29	H Lundbeck As	Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
CN116390712A (zh)	2020-07-29	2023-07-04	阿勒根制药国际有限公司	治疗偏头痛
CA3206184A1 (en)	2020-12-22	2022-06-30	Allergan Pharmaceuticals International Limited	Treatment of migraine
EP4301362A1 (en)	2021-03-02	2024-01-10	CGRP Diagnostics GmbH	Treatment and/or reduction of occurrence of migraine
US20250109188A1 (en)	2021-08-24	2025-04-03	Cgrp Diagnostics Gmbh	Preventative treatment of migraine
EP4408418A1 (en)	2021-09-27	2024-08-07	Allergan Pharmaceuticals International Limited	Combination comprising atogepant for treating migraine
CN116903616B (zh) *	2023-07-17	2025-08-01	江西同和药业股份有限公司	一种瑞美吉泮中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
DE19503160A1 (de) *	1995-02-01	1996-08-08	Bayer Ag	Verwendung von Phenylcyclohexylcarbonsäureamiden
WO1996035713A1 (en)	1995-05-08	1996-11-14	Pfizer, Inc.	Dipeptides which promote release of growth hormone
JP2002525371A (ja) *	1998-09-30	2002-08-13	メルクシャープエンドドームリミテッド	Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
PT1120415E (pt)	1998-09-30	2003-12-31	Taisho Pharmaceutical Co Ltd	Compostos de isoxazoliltiofeno substituido
ES2616539T3 (es) *	2002-06-05	2017-06-13	Bristol-Myers Squibb Company	Antagonistas de receptores de péptidos relacionados con el gen de calcitonina
ATE466860T1 (de) *	2003-04-15	2010-05-15	Merck Sharp & Dohme	Cgrp-rezeptorantagonisten

2004
- 2004-04-07 JO JO200445A patent/JO2355B1/en active
- 2004-04-09 BR BRPI0409601-0A patent/BRPI0409601A/pt not_active IP Right Cessation
- 2004-04-09 KR KR1020057019692A patent/KR100769030B1/ko not_active Expired - Fee Related
- 2004-04-09 JP JP2006509818A patent/JP3967766B2/ja not_active Expired - Fee Related
- 2004-04-09 RU RU2005135440/04A patent/RU2308458C2/ru not_active IP Right Cessation
- 2004-04-09 NZ NZ543357A patent/NZ543357A/en not_active IP Right Cessation
- 2004-04-09 WO PCT/US2004/011280 patent/WO2004092168A1/en not_active Ceased
- 2004-04-09 DK DK04749887T patent/DK1638969T3/da active
- 2004-04-09 AT AT04749887T patent/ATE413400T1/de active
- 2004-04-09 MX MXPA05011166A patent/MXPA05011166A/es active IP Right Grant
- 2004-04-09 WO PCT/US2004/010851 patent/WO2004092166A2/en not_active Ceased
- 2004-04-09 EP EP04749887A patent/EP1638969B1/en not_active Expired - Lifetime
- 2004-04-09 PT PT04749887T patent/PT1638969E/pt unknown
- 2004-04-09 CA CA002522220A patent/CA2522220C/en not_active Expired - Fee Related
- 2004-04-09 CN CNB2004800161154A patent/CN100384843C/zh not_active Expired - Fee Related
- 2004-04-09 SI SI200430961T patent/SI1638969T1/sl unknown
- 2004-04-09 HR HR20080666T patent/HRP20080666T3/xx unknown
- 2004-04-09 ES ES04749887T patent/ES2314417T3/es not_active Expired - Lifetime
- 2004-04-09 EP EP08105721.8A patent/EP2039694B1/en not_active Expired - Lifetime
- 2004-04-09 PL PL04749887T patent/PL1638969T3/pl unknown
- 2004-04-09 DE DE602004017608T patent/DE602004017608D1/de not_active Expired - Lifetime
- 2004-04-09 AU AU2004230926A patent/AU2004230926B2/en not_active Ceased
- 2004-04-12 PE PE2004000364A patent/PE20050020A1/es not_active Application Discontinuation
- 2004-04-13 CL CL200400788A patent/CL2004000788A1/es unknown
- 2004-04-13 AR ARP040101238A patent/AR045887A1/es active IP Right Grant
- 2004-04-14 TW TW093110393A patent/TWI314931B/zh not_active IP Right Cessation
- 2004-05-04 US US10/838,835 patent/US6953790B2/en not_active Expired - Lifetime
- 2004-09-04 UA UAA200510685A patent/UA82877C2/uk unknown
2005
- 2005-06-14 US US11/152,537 patent/US7235545B2/en not_active Expired - Lifetime
- 2005-09-29 IS IS8055A patent/IS2759B/is unknown
- 2005-10-11 MA MA28550A patent/MA27728A1/fr unknown
- 2005-10-12 CO CO05104372A patent/CO5640130A2/es active IP Right Grant
- 2005-10-12 EC EC2005006097A patent/ECSP056097A/es unknown
- 2005-11-14 NO NO20055375A patent/NO327655B1/no not_active IP Right Cessation
2007
- 2007-03-14 US US11/724,066 patent/US7452903B2/en not_active Expired - Lifetime
2008
- 2008-04-09 US US12/082,233 patent/US7534784B2/en not_active Expired - Lifetime
2009
- 2009-01-15 CY CY20091100053T patent/CY1108714T1/el unknown
- 2009-04-03 US US12/417,911 patent/US7772224B2/en not_active Expired - Lifetime
2010
- 2010-07-07 US US12/831,802 patent/US7893052B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP2039694B1 (en)	2014-03-26
US20050256098A1 (en)	2005-11-17
CO5640130A2 (es)	2006-05-31
US7534784B2 (en)	2009-05-19
US20070225272A1 (en)	2007-09-27
NO327655B1 (no)	2009-09-07
RU2308458C2 (ru)	2007-10-20
PT1638969E (pt)	2009-01-16
DK1638969T3 (da)	2009-01-26
AU2004230926A1 (en)	2004-10-28
US20080280857A1 (en)	2008-11-13
WO2004092166A3 (en)	2005-01-20
HRP20080666T3 (en)	2009-01-31
US20040229861A1 (en)	2004-11-18
MA27728A1 (fr)	2006-01-02
DE602004017608D1 (de)	2008-12-18
NZ543357A (en)	2008-08-29
US6953790B2 (en)	2005-10-11
US7772224B2 (en)	2010-08-10
AR045887A1 (es)	2005-11-16
CN100384843C (zh)	2008-04-30
PL1638969T3 (pl)	2009-04-30
RU2005135440A (ru)	2006-03-20
US7893052B2 (en)	2011-02-22
US20090192139A1 (en)	2009-07-30
KR20050121734A (ko)	2005-12-27
ECSP056097A (es)	2006-03-01
ATE413400T1 (de)	2008-11-15
HK1090922A1 (en)	2007-01-05
EP2039694A1 (en)	2009-03-25
EP1638969A2 (en)	2006-03-29
US7452903B2 (en)	2008-11-18
TWI314931B (en)	2009-09-21
PE20050020A1 (es)	2005-02-18
TW200505903A (en)	2005-02-16
SI1638969T1 (sl)	2009-02-28
JO2355B1 (en)	2006-12-12
WO2004092168A1 (en)	2004-10-28
KR100769030B1 (ko)	2007-10-22
ES2314417T3 (es)	2009-03-16
NO20055375L (no)	2005-11-14
CN1802376A (zh)	2006-07-12
CA2522220C (en)	2009-06-23
WO2004092166A2 (en)	2004-10-28
JP3967766B2 (ja)	2007-08-29
CL2004000788A1 (es)	2005-02-25
JP2006523697A (ja)	2006-10-19
EP1638969B1 (en)	2008-11-05
MXPA05011166A (es)	2005-12-14
UA82877C2 (en)	2008-05-26
US20100298303A1 (en)	2010-11-25
CA2522220A1 (en)	2004-10-28
US7235545B2 (en)	2007-06-26
BRPI0409601A (pt)	2006-04-18
AU2004230926B2 (en)	2008-07-17
IS8055A (is)	2005-09-29
CY1108714T1 (el)	2014-04-09

Publication	Publication Date	Title
IS2759B (is)	2011-10-15	CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi
NO20052496D0 (no)	2005-05-24	Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
NO20052285D0 (no)	2005-05-10	Faste, partikkelformige, antifungale preparater for farmasoytisk anvendelse
DK1732917T3 (da)	2009-11-30	Udvalgte CGRP-antagonister, fremgangsmåde til fremstilling deraf, samt anvendelse deraf som lægemiddel
NO20052855D0 (no)	2005-06-13	Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
DK1951661T3 (da)	2012-09-03	Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser deraf
NO20052739D0 (no)	2005-06-07	CCR5-antagonister som medikamenter
NO20052493D0 (no)	2005-05-24	Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
DK1400518T3 (da)	2007-03-26	Heterocycliske forbindelser og lægemidler
DK1523488T3 (da)	2009-03-16	Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
KR20050009999A (ko)	2005-01-26	약제학적 제제
DK1448591T3 (da)	2008-09-29	17-alpha-alkyl-17-beta-oxy-estratriener og mellemprodukter til fremstilling heraf, anvendelse af 17-alpha-alkyl-17-beta-oxy-estratriener til fremstilling af lægemidler samt farmaceutiske præparater
DK1427730T3 (da)	2006-11-06	Nye dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
DE60105922D1 (de)	2004-11-04	Tragbares, autarkes Medikamenteninfusionsgerät
DK1951658T3 (da)	2012-10-15	Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser
DE602004028934D1 (de)	2010-10-14	Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
DK1463759T3 (da)	2013-08-12	Ligand for den G-proteinkoblede receptor GPR43 og anvendelser deraf
DK1590321T3 (da)	2010-08-09	Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
DK1513836T3 (da)	2006-09-11	Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
DK1831240T3 (da)	2009-11-23	18-methyl-19-nor-17pregn-4-en-21, 17-carbolactoner samt farmaceutiske præparater, der indeholder disse
NO20051983D0 (no)	2005-04-22	3-fenyl-substituert pyridoindolon, fremstilling derav og terapeutisk anvendelse derav.
NO20040499L (no)	2004-03-31	Substituerte pyridin-4-oner og deres andvendelse som gonadotropin-frigjorende hormon reseptor antagonister.
IS7798A (is)	2005-04-11	Efnasambönd, lyfjablöndur og aðferðir
DK1753725T3 (da)	2013-05-27	Tetra-hydro-iso-quinolinsulfonamidderivater, fremstilling og terapeutisk anvendelse heraf.
DE50304722D1 (de)	2006-10-05	Fungizide Wirkstoffkombinationen